The PIN1 Antibody is a research reagent designed to detect and study the peptidylprolyl cis/trans isomerase PIN1 (peptidylprolyl cis/trans isomerase, NIMA-interacting 1), a critical enzyme involved in protein conformational regulation. PIN1 catalyzes the cis/trans isomerization of phosphorylated serine/threonine-proline motifs, influencing protein stability, localization, and function . Its dysregulation is implicated in cancer, neurodegenerative diseases, viral infections, and cardiovascular disorders .
PIN1 antibodies are engineered to bind specific epitopes of the PIN1 protein. Key characteristics include:
Target Epitope: C-terminal region (aa 41–163 in human PIN1) or phosphorylated residues (e.g., Ser71) .
Host/Clonality: Mouse monoclonal (e.g., G-8) , rabbit polyclonal (e.g., AF6430) , or mouse monoclonal (e.g., MAB2294) .
Reactivity: Broad species compatibility, including human, mouse, rat, and non-human primates .
PIN1 antibodies enable diverse experimental approaches:
Western Blotting (WB): Detects PIN1 in denatured lysates (18–20 kDa) .
Immunohistochemistry (IHC): Localizes PIN1 in paraffin-embedded tissues (cytoplasm/nucleus) .
Immunoprecipitation (IP): Identifies PIN1 protein-protein interactions .
Immunofluorescence (IF): Visualizes PIN1 subcellular distribution .
Oncogenic Roles: PIN1 stabilizes oncogenes (e.g., β-catenin, cyclin D1) and destabilizes tumor suppressors (e.g., p53, PML) . High PIN1 expression correlates with poor prognosis in cancers like triple-negative breast cancer (TNBC) .
Biomarker Potential: In TNBC, high PIN1 expression predicts improved response to DNA-damaging chemotherapy (e.g., paclitaxel, cisplatin) .
SARS-CoV-2: PIN1 inhibitors block viral replication by disrupting viral transcription and cytopathic effects .
HIV-1: PIN1 facilitates capsid uncoating, reverse transcription, and genomic integration .
Atherosclerosis: PIN1 promotes vascular inflammation and endothelial dysfunction via TGF-β/SMAD and VEGF pathways .
Hypertension: PIN1 enhances eNOS activity and VEGF signaling, contributing to endothelial remodeling .
SARS-CoV-2 Propagation: PIN1 inhibition reduces viral mRNA/protein synthesis and alleviates cytopathic effects in VeroE6/TMPRSS2 cells .
TNBC Treatment Response:
Angiogenesis: PIN1 upregulates HIF-1α/VEGF and NF-κB pathways, promoting cancer-induced angiogenesis .
Apoptosis Regulation: PIN1 inhibits proapoptotic factors (e.g., BAX, FADD) and promotes antiapoptotic proteins (e.g., Mcl-1) .